Advanced Filters
noise

adenocarcinoma Clinical Trials

A listing of adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,396 clinical trials
D Dong Il Gwon, MD, PhD

Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard treatment.

19 - 79 years of age All Phase N/A
K Kangshun Zhu, MD

SIRT for Potentially Resectable HCC

This study is conducted to evaluate the efficacy and safety of Y-90 selective internal radiation therapy (SIRT) in patients with potentially resectable hepatocellular carcinoma (HCC).

18 - 75 years of age All Phase N/A
H Huikai Li, Doctor

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma

20 - 79 years of age All Phase 2
G Guangxin Li

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Patients with hepatocellular carcinoma with PVTT can benefit from surgical resection and radiotherapy. As the rapid development of systematic treatment in hepatocellular carcinoma, ICIs neoadjuvant therapy is being actively explored .But there is no evidence to prove the safety and efficacy of lenvatinib and anti-PD1 antibody combined with radiotherapy neoadjuvant …

18 - 70 years of age All Phase 1
B Bingjia He, MD

Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs

To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and protein drugs into advanced solid tumors.

18 - 99 years of age All Phase 2
P Po-Yueh Chen, MD

The Application of Serum DNA Methylation for Patients With HCC

The goal of this single-arm prospective study is to evaluate the application of serum DNA methylation for HCC patients with normal alpha-fetoprotein. The main question it aims to answer is . Is the dynamic change of serum DNA methylation correlated to recurrence or treatment response of HCC

20 years of age All Phase N/A
H Hyun Hee Lee

Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma

To compare safety and efficacy of microwave ablation with simultaneous ablation using two antennas versus overlapping ablation with single antenna for small hepatocellular carcinoma

20 - 85 years of age All Phase N/A
H Hao Feng, MD, PhD

GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous armored GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.

18 - 75 years of age All Phase N/A
M Michael Lock, M.D.

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic …

18 years of age All Phase 3
C Claudia H Sweeney

Durvalumab and Tremelimumab in Resectable HCC

Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of …

18 years of age All Phase 2

Simplify language using AI